Clinical trials: Placebo Drug Interaction
Epilepsy
A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record.
- Trial name
- NCT02607891
- Testing
- GWP42003-P
- Where
- 5 sites in Netherlands, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- Jazz Pharmaceuticals
Autism Spectrum Disorder, Autism
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of >/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and…
- Trial name
- NCT05067582
- Testing
- L1-79
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Yamo Pharmaceuticals LLC
Malaria
L9LS-R21 Interaction
This is a randomized, double-blind, placebo-controlled trial in 2 parts evaluating the effect of 1-time administration of the monoclonal antibody (MAb) L9LS to healthy Malian participants on the immunogenicity of subsequent…
- Trial name
- NCT07208760
- Testing
- Single dose of 1800 mg L9LS SC (12mL), Single dose of 225 mg L9LS SC (1.5mL)
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Autism Spectrum Disorders
Dietary Fatty Acids Improve Social Impairment in Autism Spectrum Disorders
In a double-blind, placebo-controlled 16-week trial investigators administered daily doses of either youths with autism spectrum disorders.ARA and DHA supplementation significantly improved communication as well as social…
- Trial name
- Fatty acid (NCT01154894)
- Testing
- Aravita including arachidonic acid and docosaheaenoic acid
- Volunteers
- 13 people
- Sponsor
- Ashiya University
Epilepsy
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P.
- Trial name
- NCT02607904
- Testing
- GWP42003-P
- Where
- 5 sites in Netherlands, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Jazz Pharmaceuticals